Company Filing History:

8 out of 145

Connaught Laboratories Limited

patents

6 out of 75

Aventis Pasteur Limited

Years Active: 1999-2007

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7229625 - Retrovirus-like particles made non-infectious by a plurality of mutations (2007-06-12),

2. 7220826 - Expressing gp140 fragment of primary HIV-1 isolate (2007-05-22),

3. 6923970 - Retrovirus-like particles made non-infectious by a plurality of mutations (2005-08-02),

4. 6544752 - Anigenically-marked non-infectious retrovirus-like particles (2003-04-08),

5. 6544527 - Non-infectious, immunogenic, human immunodeficiency virus-like particles devoid of long terminal repeats and a functional pol coding region (2003-04-08),

6. 6518030 - Antigentically-marked non-infectious retrovirus-like particles (2003-02-11),

7. 6451322 - Retrovirus like particles made non infectious by a plurality of mutations (2002-09-17),

8. 6395714 - Expressing gp140 fragment of primary HIV-1 isolate (2002-05-28),

9. 6342228 - Diagnostic kits comprising genetically engineered human immunodeficiency virus-like particles containing heterologous antigenic markers (2002-01-29),

10. 6291157 - Antigenically-marked non-infectious retrovirus-like particles (2001-09-18),

11. 6235523 - Vectors for DNA immunization against cervical cancer (2001-05-22),

12. 6080408 - Human immunodeficiency virus type 1 nucleic acids devoid of long (2000-06-27),

13. 6025125 - Methods for the detection of HIV-specific immune responses employing (2000-02-15),

14. 5955342 - Non-infectious, replication-defective, self-assembling HIV-1 viral (1999-09-21),

15. 5889176 - Nucleic acid molecules encoding non-infectious, non-replicating, HIV (1999-03-30),

Title: The Innovations of Roy Persson

Introduction

Roy Persson is a notable inventor based in North York, Canada. He has made significant contributions to the field of biotechnology, particularly in the development of non-infectious retrovirus-like particles and immune response elicitation against HIV-1. With a total of 17 patents to his name, his work has had a profound impact on medical research and therapeutic applications.

Latest Patents

Among his latest patents, one focuses on retrovirus-like particles made non-infectious by a plurality of mutations. These particles contain specific mutations that reduce gag-dependent RNA-packaging, eliminate reverse transcriptase activity, integrase activity, and RNase H activity through genetic manipulation. This innovation has potential utility in in vivo administration, including applications for humans and in diagnostic processes. Another significant patent involves expressing the gp140 fragment of a primary HIV-1 isolate. This patent describes a vector designed to elicit an immune response in a host, featuring a gene encoding the gp140 protein of the HIV-1 isolate BX08, controlled by a promoter for effective protein expression.

Career Highlights

Throughout his career, Roy Persson has worked with prominent companies in the biotechnology sector, including Connaught Laboratories Limited and Aventis Pasteur Limited. His experience in these organizations has contributed to his expertise and the development of his innovative patents.

Collaborations

Roy has collaborated with notable colleagues such as Benjamin Rovinski and Shi-Xian Cao, further enhancing the scope and impact of his research.

Conclusion

Roy Persson's contributions to biotechnology through his patents and collaborations have positioned him as a significant figure in the field. His work continues to influence advancements in medical research and therapeutic strategies.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com